US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Moderna, Inc. - Common Stock (NQ:MRNA)

225.00 +28.00 (+14.21%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Why Moderna Stock Surged Today ↗
The biotech could play a significant role in a national effort to combat cancer. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street ↗
Have Moderna’s shares risen too much, too fast? 
Via The Motley Fool
Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Friday. ↗
Via Chartmill
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? ↗
Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential. 
Via The Motley Fool
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Is Now the Time to Cash Out of the S&P 500's Top 3 Stocks of 2026? ↗
These stocks have all soared more than 350% this year. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
Tuesday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
A Soft Jobs Report Takes the Heat Off Rates, and Nvidia Closes In on $6 Trillion ↗
Via Chartmill
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu... 
Via StockStory
Topics Economy
News headline image
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR) rose by 13.6% ... 
Via StockStory
Topics Intellectual Property
News headline image
If I Could Tell Every New Investor 1 Thing About Building Wealth in the Stock Market, It's This ↗
New investors might be eager to jump in during a bull market. 
Via The Motley Fool
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
News headline image
Prediction: Moderna Stock Will Soar 100% by 2030 ↗
The company could enter a fresh growth phase. 
Via The Motley Fool
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Why Moderna (MRNA) Shares Are Falling Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutr... 
Via StockStory
Wednesday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Juan Andres to Return to Moderna as Chief Operating Officer Jerh Collins to Retire Following Four Years of Leadership at Moderna 
From Moderna, Inc.
Via ACCESS Newswire
News headline image
2 S&P 500 Stocks to Consider Right Now and 1 We Question
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside? ↗
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase. 
Via The Motley Fool
News headline image
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock? ↗
Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock. 
Via The Motley Fool
These S&P500 stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Thursday. ↗
Via Chartmill
News headline image
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID ↗
Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program... 
Via MarketBeat
News headline image
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? ↗
The company is looking to prove it can achieve significant success outside the coronavirus market. 
Via The Motley Fool
News headline image
Is Moderna Stock a Buy After Its Melanoma Breakthrough? ↗
Moderna's story is changing fast, but the stock is already pricing in a lot. See what the Phase 3 cancer result really proves, what could come next, and where the biggest risk still sits. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >